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Abst rac t 
Introduction: Patients with systemic sclerosis experience endothelial dysfunction and damage even in the absence 
of clinical manifestations. 
Aim: To evaluate various methods for assessing the endothelial function for their applicability to clinical practice.
Material and methods: Forty-two patients (7 men and 35 women) with systemic sclerosis and 36 controls (11 men 
and 25 women) matched for age, sex, body mass index, smoking habit, and comorbidities were enrolled in the 
study. We assessed each participant for typical risk factors for cardiovascular diseases and measured serum levels 
of vascular cell adhesion molecule-1 (VCAM-1) and thrombomodulin together with flow-mediated dilatation (FMD) 
of the brachial artery and intima-media thickness (IMT) of the common carotid artery using ultrasonography.
Results: Patients with systemic sclerosis did not differ from controls in serum levels of VCAM-1 and thrombo-
modulin, however, the statistical analysis with adjustment for potential confounders revealed increased levels of 
thrombomodulin in the patients (p = 0.03). They also had a 45% lower relative increase of FMD (FMD%), and 13% 
higher IMT (p < 0.01, both, also after adjustment for potential confounders). In a simple regression model, lower 
FMD% was determined by age (β = –0.57, 95% confidence interval (CI): –0.72 to –0.43) and C-reactive protein levels  
(β = –0.38, 95% CI: –0.55 to –0.22). Thicker IMT was related to age (β = 0.64, 95% CI: 0.52–0.67), glomerular filtration 
rate (β = –0.34, 95% CI: –0.5 to –0.18), and blood thrombomodulin levels (β = 0.45, 95% CI: 0.13–0.76).
Conclusions: Patients with systemic sclerosis present with endothelial dysfunction which may be detected using 
ultrasonographic methods. The exact mechanism of observed abnormalities is unknown, but it is possibly related 
to the chronic inflammation and ischemia-reperfusion injury.
Key words: atherosclerosis, endothelium, flow-mediated dilatation, intima-media thickness, scleroderma.
Introduction
Systemic sclerosis (scleroderma) is a chronic disease 
of the connective tissue characterized by thickening and 
fibrosis of the skin and internal organs. Historically, 
there are two major disease subsets: the diffuse type, 
which is associated with a high risk of pulmonary ar-
terial hypertension, acute renal injury and diffuse skin 
involvement (extremities proximal to elbows and knees, 
chest, abdomen and back) [1]; and the limited type, 
related to sclerodactyly and Raynaud’s phenomenon, 
calcinosis, esophageal dysmotility, telangiectasia and 
limited skin involvement (face, neck and extremities 
distal to elbows and knees) [1, 2]. Vascular damage in 
both systemic sclerosis subsets is mainly microvascular 
and Raynaud’s phenomenon is the earliest manifesta-
tion of the disease. The other clinical symptoms related 
to microvascular abnormalities are digital ulcerations, 
renal insufficiency and pulmonary arterial hyperten-
sion [3, 4]. Macrovascular damage is less frequent but 
increased stiffness of large arteries, plaque presence 
and increased intima-media thickness of the common 
carotid artery (IMT) have also been reported [1, 5, 6]. 
Systemic sclerosis is associated with an increased risk 
of myocardial infarct, stroke and peripheral artery dis-
ease, although exact mechanisms of these abnormali-
ties remain unknown [7, 8].
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Endothelial dysfunction seems to be a key mecha-
nism in the pathophysiology of systemic sclerosis. In 
many studies the function of the endothelium was mea-
sured through flow-mediated dilatation (FMD) of the bra-
chial artery which evaluates the response to shear, the 
subsequent release of nitric oxide and dilatation of the 
vessel [9–18]. Several studies have found elevated IMT 
in patients with systemic sclerosis, which is considered 
as an indicator of atherosclerosis [5, 9, 12, 16, 18]. These 
aforementioned studies, however, conflict in results and 
were performed on small groups of patients. Endothelial 
damage can also be assessed through laboratory tests. 
It is related to the higher expression of adhesion mol-
ecules on endothelium, such as E-selectin, endothelin-1, 
and vascular cell adhesion molecule-1 (VCAM-1) which 
might be sheared into the blood stream. Activated en-
dothelium also releases other molecules, such as von 
Willebrand factor, soluble thrombomodulin, and tissue 
plasminogen factor, which could be the markers of pro-
coagulant activity [19].
Aim
Taking into account the ambiguous results of previ-
ously published studies on endothelial dysfunction in 
systemic sclerosis, we sought to determine the validity 
laboratory parameters of endothelium damage, such as 
serum concentration of thrombomodulin and VCAM-1, as 
well as to evaluate, in ultrasound, FMD of the brachial 
artery and measure IMT of the common carotid arteries 
[5, 9, 12, 16, 18]. Finally, we analysed their relationships 
to the clinical features of the systemic sclerosis and an-
tibodies levels. We believe that due to the rarity of that 
disease every report is valuable. 
Material and methods
Our study follows the case-control observational, ret-
rospective format and received approval from the Bioeth-
ics Committee of Jagiellonian University Medical College 
(9th May 2013, number of protocol: KBET/79/B/2013). All 
study participants received an explanation of the meth-
odology and safety protocol and gave written consent to 
be included in the study.
The 42-patient case group was made up of 35 women 
and 7 men. They were enrolled in the period from 2014 
to 2017 at the II Department of Internal Medicine, Jagiel-
lonian University, Medical College, Krakow, a diagnostics 
and treatment centre for autoimmune diseases in south-
ern Poland. These patients were all previously diagnosed 
with systemic sclerosis according to the criteria of the 
American College of Rheumatology and all evaluated for 
the presence of typical systemic sclerosis autoantibodies 
such as anti-centromere, anti-topoisomerase I (anti-Scl-70, 
AC-29), anti-RNA polymerase III antibodies, and anti-PM/
Scl antibodies [20]. Candidates for the case group were 
excluded from the study if they had confirmed atheroscle-
rosis, angina pectoris, congestive heart failure, liver failure, 
uncontrolled hypertension, or cancer. Other comorbidities 
that did not disqualify a patient but were recorded include 
hypertension (a history of blood pressure > 140/90 mm Hg 
or current antihypertensive treatment), hypercholesterol-
emia (a serum total cholesterol > 5.2 mmol/l or ongoing 
antihypercholesterolemic therapy), and diabetes mellitus 
(use of insulin or oral hypoglycaemic agents, or fasting se-
rum glucose > 7.0 mmol/l).
The 36-individual healthy control group was made up 
of 25 women and 11 men that matched the case group as 
to gender, age, body mass index (BMI) and smoking hab-
it. They were selected with the same exclusion criteria 
as the studied group and their concomitant morbidities 
were likewise recorded. The control group was enrolled 
from the hospital’s personnel and their relatives.
Laboratory analysis 
Hospital staff collected fasting blood samples in the 
morning from the antecubital vein with the least possible 
tourniquet use. Lipid profile, levels of glucose, alanine 
transaminase, urine, creatinine for glomerular filtration 
rate (eGFR), and complete blood count were measured us-
ing routine laboratory techniques and C-reactive protein 
(CRP) with the Johnson & Johnson VITROS 250. We mea-
sured serum parameters specific to this study from blood 
samples centrifuged in separation tubes at 2,000 ×g 
for 10 min at room temperature within 2 h of collection. 
Standardized ELISA method (all, R&D Systems, Minne-
apolis, MN, USA) was used in order to measure Interleu-
kin (IL)-6, VCAM-1, and soluble thrombomodulin levels. 
Antinuclear antibodies (ANA) were analysed using indi-
rect immunofluorescence tests (ThermoFisher, Waltham, 
USA) and antigen-specific ELISA for autoantibodies 
against topoisomerase I, centromeres, RNA polymerase 
III, NOR 90, PM-Scl, Ku, PDGFR, fibrillarin, and Ro-52 
(EUROIMMUN, Lübeck, Germany).
Ultrasound examinations
Two independent experts performed the ultrasound 
studies using the Siemens Acuson Sequoia 512 with 
a 10 MHz linear array ultrasonic transducer (Mountain 
View, Ca, USA). They performed the studies in a dark, qui-
et room with the subjects in a supine position for 10 min 
and having fasted for 10 h. They measured flow-mediated 
dilation of the brachial artery and intima-media thickness 
of the carotid artery. They both made three consecutive 
measurements of every parameter and we recorded the 
mean of the six measurements for analysis. The ultraso-
nographers then performed a transthoracic echocardio-
gram (TTE) on each subject using standard methods [21]. 
Brachial artery ultrasonography. Celemayer’s method 
was used to measure FMD of the brachial artery [22]. We 
used the technique described in detail in our previous 
papers [23, 24]. The baseline sagittal diameter (D1) of 
a distal part of the brachial artery was measured in the 
Advances in Dermatology and Allergology 4, August/2020
Endothelial dysfunction in patients with systemic sclerosis
497
M-presentation with a 10 MHz linear array ultrasonic 
transducer placed 2–3 cm proximal to the arterial bifurca-
tion. A sphygmomanometer cuff was then placed on the 
forearm below the elbow and inflated to 200 mm Hg for 
5 min and released. One minute after releasing the cuff, 
the brachial artery diameter was measured a second 
time (D2) at the same point. FMD is the increase of the 
brachial artery diameter after deflation of the cuff and 
is expressed as a percentage of the baseline diameter 
(FMD % = ((D2 – D1)/D1) × 100%). We recorded the mean 
of the FMD of both arms for analysis.
Intima-media thickness of the common carotid artery. 
As previously described by us, the IMT of the carotid ar-
tery was measured by ultrasound with a 10 MHz linear 
transducer. The thickness of the anterior and posterior 
walls of the common carotid arteries was measured in 
the longitudinal projection immediately proximal to their 
bifurcation [23, 24]. We recorded the mean value of the 
IMT on the right and left side for analysis.
Statistical analysis 
The results of the case and control groups were com-
pared using Statistica 12.5 software. The continuous vari-
ables all had non-normal distribution according to the 
Shapiro-Wilk test. We report them here as median and 
interquartile ranges and compare them using the Mann-
Whitney U-test. Categorical variables are given as percent-
ages and compared by χ2 test. Age, sex, BMI, and comor-
bidities, such as arterial hypertension, diabetes mellitus, 
and hypercholesterolemia were considered as potential 
confounders. Therefore, the main outcome results: FMD%, 
IMT, VCAM-1, and thrombomodulin were log-transformed 
and a one way covariance analysis (ANCOVA) was per-
formed to adjust for them. The univariate linear regression 
models with adjustment for BMI, age, and sex were used 
to analyse associations between two selected parameters. 
Markers of endothelial injury were assessed using simple 
regression models. Results were considered significant 
when the p-value was less than 0.05.
Results
Characteristics of patients and controls
Table 1 presents characteristics of patients with sys-
temic sclerosis and controls. As it has been shown, both 
groups were similar in age, sex, BMI, smoking habits and 
comorbidities (hypertension, diabetes mellitus and hy-
percholesterolemia). 
Characteristics of the patients with systemic sclerosis 
at the time of evaluation are given in Table 2. The median 
duration of the disease was 4 (range: 1–7) years and the 
majority of the patients (69%, n = 29) had a diffuse type 
of the disease. All of the systemic sclerosis patients had 
positive results of antinuclear antibodies in indirect im-
munofluorescence. The disease specific anti-topoisom-
erase I antibodies were present in half of them. Other 
types of antibodies, such as anti-centromere, anti-RNA 
polymerase III, anti-Ro-52, and anti-Ku antibodies had 
lower prevalence. Raynaud’s phenomenon was the most 
common clinical manifestation, followed by interstitial 
lung disease, skin lesions on the fingers, and pulmonary 
arterial hypertension. Half of the patients with systemic 
sclerosis were being treated with systemic glucocortico-
steroids at the time of evaluation. They were also receiv-
ing or had received other immunosuppressive agents 
such as azathioprine, cyclophosphamide, methotrex-
ate, mycophenolate mofetil, or rituximab. Among other 
medications, the most common were statins, β-blockers, 
angiotensin converting enzyme inhibitors or angioten-
sin receptor antagonists, diuretics and calcium channel 
blockers. 
 Basic laboratory tests and basic transthoracic 
echocardiographic parameters
Table 1 presents the results of basic laboratory tests 
and TTE parameters. As expected, patients with systemic 
sclerosis had higher inflammatory markers, such as CRP 
and IL-6, as well as a lower haemoglobin level. Surpris-
ingly, individuals in the control group were characterized 
by a higher total cholesterol level and creatinine concen-
tration (in all subjects in normal range).
In TTE, patients with systemic sclerosis had a slightly 
lower ejection fraction, thicker interventricular septum and 
higher systolic pulmonary artery pressure (Table 1). More-
over, those with the diffuse type of the disease were char-
acterized by larger left atrium (3.9 (3.5–4.2) vs. 3.9 (3.8–3.9) 
cm, p = 0.005) and left ventricle (both, diastolic diameter 
4.6 (4.4–4.9) vs. 4.3 (4.2–4.6) cm, p = 0.04 and systolic 
diameter 3 (2.9–3.1) vs. 2.9 (2.8–2.9) cm, p = 0.02), thicker 
interventricular septum (1.1 (1–1.2) vs. 0.9 (0.8–1.1) cm, 
p = 0.003) and thicker left ventricle posterior wall 
(1 (0.9–1.1) vs. 0.8 (0.9–0.9) cm, p = 0.007). 
Laboratory markers of endothelial injury 
Patients with systemic sclerosis had similar serum 
levels of VCAM-1 and thrombomodulin as compared 
to healthy individuals (Table 3). However, the ANCOVA 
analysis performed with adjustment for potential con-
founders revealed that levels of thrombomodulin, but not 
VCAM-1, were increased in the systemic sclerosis group 
(p = 0.03). Both laboratory markers of endothelial injury 
remained in a strong positive association between each 
other in patients and in controls (β = 0.58, 95% confi-
dence interval (CI): 0.4–0.76, β = 0.44, 95% CI: 0.28–0.6, 
respectively). 
In systemic sclerosis patients, we documented 
a strong positive association between thrombomodu-
lin and kidney function (β = 0.84, 95% CI: 0.53–1.15, 
β = 0.69, 95% CI: 0.44–0.93, for creatinine and urea 
blood levels, respectively). For VCAM-1 such relation was 
Advances in Dermatology and Allergology 4, August/2020498
R. Pacholczak-Madej, P. Kuszmiersz, S. Bazan-Socha, J. Kosałka-Węgiel, T. Iwaniec, L. Zaręba, S. Kielczewski, A. Rams, 
J.A. Walocha, J. Musiał, J. Dropiński
demonstrated only for serum creatinine concentrations 
(β = 0.67, 95% CI: 0.39–0.95). Additionally, thrombomod-
ulin in the patients with systemic sclerosis was related to 
the interventricular septum and posterior wall thickness 
(β = 0.78, 95% CI: 0.5–1.06, β = 0.83, 95% CI: 0.56–1.1, 
respectively), as well as the CRP level (β = 0.57, 95% CI: 
0.31–0.83). 
Patients with systemic or limited disease had similar 
VCAM-1 and thrombomodulin levels. Likewise, comorbidi-
ties, treatment mode and type of antibodies had no im-
pact on either laboratory marker of endothelial damage.
Ultrasound parameters of endothelial injury
As shown in Table 3, patients with systemic sclero-
sis were characterized by 45% lower FMD% and 13% 
higher IMT, as compared to the control group (p < 0.01, 
both, also after adjustment for potential confounders). 
Moreover, both these unfavourably changed ultrasound 
parameters of endothelial injury remained in a mu-
tual relationship to each other, but only in the patient 
group (β = –0.48, 95% CI: –0.63 to –0.32). In a simple 
regression model lower FMD% was determined by age 
(β = –0.57, 95% CI: –0.72 to –0.43) and CRP (β = –0.38, 
95% CI: –0.55 to –0.22). Thicker IMT was also related to 
age (β = 0.64, 95% CI: 0.52–0.67), to impaired kidney 
function (for eGFR, β = –0.34, 95% CI: –0.5 to –0.18), 
and to thrombomodulin blood levels (β = 0.45, 95% CI: 
0.13–0.76). 
For TTE parameters, IMT was positively associ-
ated with interventricular septum thickness (β = 0.28, 







Age [years] 63.5 (49–70) 57 (47–65) 0.3
Male gender, n (%) 7 (16.7) 11 (30.6) 0.15
Body mass index [kg/m2] 25 (23.3–27.5) 26.9 (23.7–28.7) 0.2
Hypertension, n (%) 17 (40.5) 10 (27.8) 0.18
Diabetes mellitus, n (%) 5 (11.9) 4 (11.1) 0.87
Hypercholesterolemia, n (%) 15 (35.7) 8 (22.2) 0.18
Smoking currently, n (%) 2 (4.8) 4 (11.1) 0.68
Smoking in the past, n (%) 12 (28.6) 11 (30.6) 0.89
Smoking [packs/years] 0 (0–5) 0 (0–3.5) 0.8
Basic laboratory tests:
High-density lipoprotein [mmol/l] 1.3 (1.1–1.5) 1.4 (1.2–1.8) 0.12
Triglycerides [mmol/l] 1.3 (1.1–2.1) 1.2 (0.8–1.8) 0.16
Glucose [mmol/l] 4.8 (4.4–5) 5 (4.8–5.2) 0.11
Creatinine [mmol/l] 67 (58–80) 74 (67–88) 0.03*
Urea [mmol/l] 5.2 (4.3–6.1) 4.9 (4.2–5.5) 0.32
Alanine transaminase [U/l] 23.5 (18.5–33) 23.5 (14.9–30) 0.48
C-reactive protein [mg/dl] 6.8 (5–18.7) 1.3 (1–2.6) < 0.01*
Interleukin-6 [pg/ml] 3.6 (2.5–10) 1.8 (1.3–2.3) < 0.01*
Echocardiographic parameters:
Left ventricular diastolic diameter [cm] 4.6–(4.3–4.9) 4.7 (4.5–4.9) 0.13
Left ventricular systolic diameter [cm] 3 (2.9–3.1) 3 (2.9–3.1) 0.56
Right ventricular diameter [cm] 2.1 (1.9–2.3) 2.1 (1.9–2.3) 1
Left atrial diameter [cm] 3.7 (3.3–4) 3.7 (3.6–4) 0.76
Left ventricle posterior wall thickness [cm] 1 (0.9–1.1) 0.9 (0.8–1) 0.14
Interventricular septal thickness [cm] 1 (0.9–1.2) 0.9 (0.9–1.1) 0.04*
Ejection fraction (%) 65 (60–67) 68 (67–68) < 0.01*
Systolic pulmonary artery pressure [mm Hg] 36 (32–42) 32 (29–34) < 0.01*
Categorical variables are presented as numbers (percentages), continuous variables as median and interquartile range. The results which are statistically sig-
nificant are marked *. n – number.
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95% CI: 0.07–0.49), and posterior wall thickness 
(β = 0.24, 95% CI: 0.03–0.45) in systemic sclerosis, while 
for FMD% such associations were not documented. IMT, 
but not FMD% was also related to the thrombomodulin 
level (β = 0.39, 95% CI: 0.11–0.67) and duration of gluco-
corticosteroids treatment (β = 0.31, 95% CI: 0.1–0.52) in 
the patient group. 
Patients with systemic or limited systemic sclerosis 
did not differ in FMD% or IMT. Similarly, disease duration, 
treatment mode, or type of antibodies had no impact on 
these variables. 
Finally, none of the analysed comorbidities had any 
influence on FMD%, but IMT was greater in those with 
hypertension (0.06 (0.05–0.065) vs. 0.075 (0.065–0.085), 
p = 0.004).
Discussion
In this study we have shown that patients with sys-
temic sclerosis present with endothelial dysfunction 
which is demonstrated by decreased FMD% and in-
creased IMT compared to well-matched controls. Also, 
the thrombomodulin level, a laboratory marker of endo-
thelium damage, was higher in the patient group, after 
adjustment for potential confounders. As expected, pa-
rameters of endothelial dysfunction were determined by 
age, but also by variables related to the specificity of the 
disease, such as kidney injury and inflammatory markers. 
Another interesting finding of this study is that IMT is 
associated with the interventricular septal and posterior 
wall thicknesses, and that it correlates with the throm-
bomodulin level. This relationship has not been reported 
before and allows us to speculate that endothelium dam-
age might be followed by a remodelling of the large ves-
sels wall, leading to increased stiffness of the arteries 
and higher afterload, as well as hypertrophy of the heart 
structures. Parameters evaluated in our study were re-
lated to the inflammatory markers, but did not depend 
on systemic sclerosis clinical manifestation, type of im-
munosuppressive treatment used currently or in the past, 
and type of antibodies present in the subgroups analysis.
Many previous reports have shown decreased FMD 
in patients with systemic sclerosis [5, 9, 12–14]. In some 
studies, however, the results were contradictory [15, 16]. 
This discrepancy might be explained by the patient se-
lection. In studies with negative results, more subjects 
presented limited systemic sclerosis, suggesting that the 
diffuse type is more prone to endothelial dysfunction. 
Our study contradicts this hypothesis because param-
eters of endothelial injury were comparable in subjects 
with a limited and diffuse subtype of disease, although 
the number of enrolled subjects with the limited form 
was much smaller than those with diffuse disease. 
Increased IMT is a diagnostic tool which indicates ongo-
ing, subclinical atherosclerosis. Our results are consistent 
with previous reports documenting thicker IMT in systemic 
sclerosis [9, 11]. However, Szucs et al. and Domsic et al. dem-
onstrated that IMT was similar in patients with systemic 
sclerosis and controls [11, 18]. Andersen et al. combined 
ultrasonographic and laboratory tests in order to evaluate 
endothelial function and have found the elevated level of 
soluble E-selectin and VCAM-1 in patients with systemic 
sclerosis with an inverse correlation to the FMD% [15].
Table 2. Clinical characteristics of the patients with 
systemic sclerosis (n = 42)
Parameter Patients
Duration of the disease [years] 4 (1–7)
Limited disease 13 (30.9)
Diffuse disease 29 (69.1)
Antinuclear antibodies presence, n (%) 42 (100)
Anti-topoisomerase I antibodies presence, n (%) 18 (42.9)
Anti-PM/Scl antibodies presence, n (%) 5 (11.9)
Anti-centromere antibodies presence, n (%) 9 (21.4)
RNA polymerase III antibodies presence, n (%) 1 (2.4)
Anti-Ku antibodies presence, n (%) 3 (7.1)
Organ involvement:
Digital ulcers, n (%) 12 (28.6)
Abnormal nailfold capillaries, n (%) 9 (21.4)
Fingertip lesions, n (%) 17 (40.5)
Telangiectasia, n (%) 6 (14.3)
Raynaud’s phenomenon, n (%) 33 (78.6)
Dysphagia, n (%) 13 (31)
Interstitial lung disease, n (%) 25 (59.5)
Treatment characteristic:
Current glucocorticosteroids, n (%) 20 (47.6)
Current glucocorticosteroids dose, recalculated  
to methylprednisolone [mg/day]
2 (0–4)
Systemic glucocorticosteroids therapy [years] 1 (0–3)
Immunosuppressive treatment (currently or in the past):
Azathioprine, n (%) 3 (7.1)
Cyclophosphamide, n (%) 48 (42.9)
Methotrexate, n (%) 6 (14.3)
Mycophenolate mofetil, n (%) 8 (19)
Rituximab, n (%) 15 (35.7)
Internal medicine medications:
Angiotensin converting enzyme inhibitors or 
angiotensin receptor antagonists, n (%)
15 (35.7)
Statins, n (%) 11 (26.2)
β-Blockers, n (%) 9 (22.4)
Diuretics, n (%) 11 (26.2)
Calcium channel blockers, n (%) 15 (35.7)
Categorical variables are presented as numbers (percentages), continuous 
variables as median and interquartile range. n – number.
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The aetiology of endothelial damage and atheroscle-
rosis in systemic sclerosis might be related to multiple 
factors, including inflammation, traditional cardiovascu-
lar risk factors and the influence of ischemia with subse-
quent reperfusion. In our study, both groups were simi-
lar in terms of cardiovascular risk factors (BMI, gender, 
smoking habits, comorbidities). Individuals in the con-
trol group had slightly higher total cholesterol and low-
density lipoprotein levels. This may be due to a higher 
prevalence of statins intake by patients with systemic 
sclerosis because the prevalence of hypercholesterolemia 
was similar in both groups. Higher creatinine levels in the 
controls (but within normal limits) are possibly due to 
greater muscle mass, although both groups had similar 
BMI. Traditional cardiovascular risk factors do not alone 
explain the accelerated atherosclerosis seen in patients 
with systemic sclerosis. The prevalence of hypertension, 
obesity, hypercholesterolemia, and diabetes were simi-
lar in other cohort studies [7, 25]. In fact, cardiovascular 
risk factors were less prevalent in patients with systemic 
sclerosis in the Australian Systemic Sclerosis Cohort 
Study, suggesting that other factors are responsible for 
the observed abnormalities [8]. Mok et al. hypothesized 
that systemic sclerosis is an independent determinant 
of coronary calcification as it is observed in the skin of 
affected subjects [25]. 
Inflammation is well established as a factor lead-
ing to vascular dysfunction and atherosclerosis. Prema-
ture atherosclerosis has been observed in patients with 
chronic inflammatory diseases such as systemic lupus 
erythematosus, antiphospholipid syndrome or systemic 
vasculitides [26–30]. We also documented higher CRP 
and IL-6 levels in the case group. Therefore, we may pos-
tulate that chronic inflammation accelerates atheroscle-
rosis in systemic sclerosis. 
Chronic endothelial damage is also caused by isch-
emia and reperfusion which lead to dysfunction and loss 
of cell integrity and tissue injury. In systemic sclerosis, tis-
sue hypoxia together with chronic blood flow reduction 
related to microvascular abnormalities is a stimulus for 
the increased expression of vascular endothelial growth 
factors (VEGF) and angiogenesis. VEGF also contributes 
to the development of fibrosis [31, 32].
Timar et al. found that rosuvastatin improves FMD, 
corrects unfavourable changes in the blood lipid profile, 
and decreases CRP, but does not reduce carotid athero-
sclerosis after a 6-month treatment period in patients 
with systemic sclerosis [33]. In their study, Kuwana et al. 
conclude that statins may be beneficial in treating vascu-
lar manifestations such as Raynaud’s phenomenon [34]. 
Therefore, statins should be advised in most patients 
with systemic sclerosis for endothelial protection but 
more clinical trials are needed to verify this hypothesis 
[35]. The other options in the treatment of endothelial 
dysfunction in systemic sclerosis are phosphodiesterase 
type 5 enzyme inhibitors (sildenafil, tadalafil), synthetic 
analogues of prostacyclin, and bosentan – an endothe-
lin receptor antagonist. They lead to the smooth muscle 
relaxation with subsequent vasodilatation, and might 
be considered in the treatment of severe Raynaud’s phe-
nomenon, digital ulcers and pulmonary arterial hyperten-
sion [36–38]. The patients enrolled in our study did not 
use the abovementioned medications, but their impact 
on parameters of endothelial dysfunction is an interest-
ing subject for further research. Obviously, patients ben-
efit most from optimal immunosuppressive treatment 
that controls inflammation and prevents consequences 
of clinically active systemic sclerosis. 
Conclusions
In this study we have demonstrated that patients 
with systemic sclerosis present with endothelial dys-
function which may be detected using ultrasonographic 
methods. FMD and IMT are easy tools with diagnostic 
and therapeutic relevance, which can help elicit a group 
of subjects with subclinical atherosclerosis. Measure-
ments of selected adhesion molecule blood levels might 
give conflicting results and should only be used in re-
search. The exact mechanism of the observed distur-
bances is unknown, however, we may speculate that it 
is due to chronic inflammation and ischemia-reperfusion 






Laboratory parameters of endothelial injury:
Vascular cell adhesion molecule-1 [ng/ml] 834.6 (703.2–1037.3) 817.7 (714.2–921.8) 0.36
Thrombomodulin [ng/ml] 4.8 (3.9–5.5) 4.4 (3.9–4.9) 0.31
Ultrasound parameters of endothelial injury and atherosclerosis:
Relative increase of flow mediated dilatation of a brachial artery 5.5 (2.6–8.3) 10 (8.5–11.4) < 0.01*
Median value of intima-media thickness of a common carotid artery [cm] 0.075 (0.06–0.08) 0.065 (0.06–0.085) 0.04*
Continuous variables are presented as median and interquartile range. The results which are statistically significant are marked *. n – number.
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injury. Although large observational studies are needed 
to verify this hypothesis, it seems that proper immu-
nosuppressive treatment might influence endothelium 
injury indirectly by reducing inflammatory response in 
systemic sclerosis subjects. 
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